News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Avastin Panel Tops Make-or-Break Period for Roche Holding AG (RHHBF.PK)



11/30/2007 6:21:28 AM

ZURICH, Nov 30 (Reuters) - Roche Holding AG's (ROG.VX: Quote, Profile, Research) richly-valued stock could take a significant hit next week if a U.S. regulatory panel advise against approving its key Avastin drug in breast cancer, analysts said. The U.S. Food and Drug Administration has delayed approval of Avastin as a first-line treatment for metastatic breast cancer but its advisory panel will review the blockbuster next Wednesday, Dec 5.

Read at Reuters


comments powered by Disqus
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES